Cargando…

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Detalles Bibliográficos
Autores principales: Brandão, Mariana, Reyal, Fabien, Hamy, Anne-Sophie, Piccart-Gebhart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555612/
https://www.ncbi.nlm.nih.gov/pubmed/31231570
http://dx.doi.org/10.1136/esmoopen-2019-000515
_version_ 1783425187248603136
author Brandão, Mariana
Reyal, Fabien
Hamy, Anne-Sophie
Piccart-Gebhart, Martine
author_facet Brandão, Mariana
Reyal, Fabien
Hamy, Anne-Sophie
Piccart-Gebhart, Martine
author_sort Brandão, Mariana
collection PubMed
description
format Online
Article
Text
id pubmed-6555612
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65556122019-06-21 Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation Brandão, Mariana Reyal, Fabien Hamy, Anne-Sophie Piccart-Gebhart, Martine ESMO Open Editorial BMJ Publishing Group 2019-05-21 /pmc/articles/PMC6555612/ /pubmed/31231570 http://dx.doi.org/10.1136/esmoopen-2019-000515 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Editorial
Brandão, Mariana
Reyal, Fabien
Hamy, Anne-Sophie
Piccart-Gebhart, Martine
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_full Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_fullStr Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_full_unstemmed Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_short Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_sort neoadjuvant treatment for intermediate/high-risk her2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555612/
https://www.ncbi.nlm.nih.gov/pubmed/31231570
http://dx.doi.org/10.1136/esmoopen-2019-000515
work_keys_str_mv AT brandaomariana neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT reyalfabien neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT hamyannesophie neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT piccartgebhartmartine neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation